Abstract:CaIPF19998, a functionally unknown gene in Candida albicans, was identified by its homology to Saccharomyces cerevisiae AIF1 gene, which is involved in cell apoptosis. In this study, ipf19998 null mutant was generated with the URA-blaster method and the construction of overexpression of CaIPF19998 was measured by quantitative RT-PCR. Minimal inhibitory concentrations determination showed that the ipf19998 overexpressed strains was more resistant to the antifungals tested than the wildtype (strain CAI4). The 2,3-bis (2-methoxy-4-nitro-5-sulfo-phenyl)-2Htetrazolium-5-carboxanilide reduction assay showed that CaIPF19998 could enhance the capacity of C. albicans biofilms formation. On Candida biofilms mode, intracellular levels of reactive oxygen species were significantly decreased and real-time RT-PCR showed that some important redox-related genes, including ALD5, CIT1, PIL1, AHP1, TRX1 and TSA1, were up-regulated in the CaIPF19998 overexpressed strains. These results demonstrate that CaIPF19998 played an important role in C. albicans biofilms formation and intracellular redox homeostasis, therefore led to a close relationship between CaIPF19998 and drug susceptibility in C. albicans.

Author Correction: CaIPF14030 negatively modulates intracellular ATP levels during the development of azole resistance in Candida albicans

Correction to: Cryptotanshinone activates AMPK-TSC2 axis leading to inhibition of mTORC1 signaling in cancer cells

Author Correction: Candida albicans gains azole resistance by altering sphingolipid composition

Corrigendum for “A Novel Kinase Subverts Aluminium Resistance by Boosting Ornithine Decarboxylase‐dependent Putrescine Biosynthesis”

Erratum: Targeting NF-κB/AP-2β Signaling to Enhance Antitumor Activity of Cisplatin by Melatonin in Hepatocellular Carcinoma Cells.

Author Correction: Tandem gene duplications contributed to high-level azole resistance in a rapidly expanding Candida tropicalis population

Correction: Corrigendum: Autophagy-associated alpha-arrestin signaling is required for conidiogenous cell development in Magnaporthe oryzae

Author Correction: BHMT Polymorphism and Susceptibility to PTE in Chinese Patients.

CaIPF19998 reduces drug susceptibility by enhancing the ability of biofilm formation and regulating redox homeostasis in Candida albicans

Corrigendum: A disintegrin and metalloproteinase domain 10 expression inhibition by the small molecules adenosine, cordycepin and N6, N6-dimethyladenosine and immune regulation in malignant cancers

Correction to: InsP3R-SEC5 interaction on phagosomes modulates innate immunity to Candida albicans by promoting cytosolic Ca 2+ elevation and TBK1 activity

Corrigendum to “Lipopolysaccharide-Induced Podocyte Injury is Regulated by Calcineurin/nfat and TLR4/MyD88/NF-κB Signaling Pathways Through Angiopoietin-like Protein 4” [genes & Diseases 9(2022) 443–455]

Corrigendum To: "pkcα/zfp64/csf1 Axis Resets the Tumor Microenvironment and Fuels Anti-Pd1 Resistance in Hepatocellular Carcinoma" [J Hepatol 77 (2022) 163-176].

Candida Albicans Gains Azole Resistance By Altering Sphingolipid Composition (Vol 9, 4495, 2018)

Corrigendum: Receptor of advanced glycation end products deficiency attenuates cisplatin-induced acute nephrotoxicity by inhibiting apoptosis, inflammation and restoring fatty acid oxidation

Author Correction: NRF2-GPX4/SOD2 axis imparts resistance to EGFR-tyrosine kinase inhibitors in non-small-cell lung cancer cells

Author Correction to ‘pharmacologically Targeting Molecular Motor Promotes Mitochondrial Fission for Anti-Cancer’ [acta Pharm Sin B 11 (2021) 1853–1866]

Author Correction to ‘FGF4 Protects the Liver from Immune-Mediated Injury by Activating CaMKKβ-PINK1 Signal Pathway to Inhibit Hepatocellular Apoptosis’ [acta Pharmaceutica Sinica B 14(2024)1605-1623]

Author Correction: Pharmacokinetics, mass balance, and metabolism of [ 14 C]vicagrel, a novel irreversible P2Y 12 inhibitor in humans

Author Correction to ‘mevalonate Improves Anti-Pd-1/pd-l1 Efficacy by Stabilizing CD274 Mrna’ [acta Pharmaceutica Sinica B 13 (2023) 2585–2600]

Author correction to ‘Discovery and identification of EIF2AK2 as a direct key target of berberine for anti-inflammatory effects’ [Acta Pharmaceutica Sinica B 13 (2023) 2138–2151]